This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Grob et al. (2011) · Archives of General Psychiatry
- Population
- 12 adults with advanced-stage cancer and clinically relevant anxiety
- Intervention
- A moderate 0.2 mg/kg psilocybin session in a controlled clinical research unit
- Comparator
- Placebo-controlled pilot design with participants acting as their own control
- Finding
- The abstract reports safe treatment sessions, lower trait anxiety at 1 and 3 months, and mood improvement by 6 months.
preliminary Historically important and clinically serious, but still a very small early-stage study.
RTHM-00397 source packet (abstract-only)
Safety
ModerateThis paper is often cited as proof, but it is better understood as a careful pilot
Concern
Small psychedelic studies in cancer settings can get overinterpreted because the topic is compelling and the unmet need is real.
What the research says
The abstract supports feasibility, short-term safety in the study setting, and an encouraging anxiety signal. It does not support the stronger claim that psilocybin was already established as a reliable treatment for cancer-related anxiety.
What to do
Read this as an early proof-of-concept study, not a finished efficacy verdict.
Grob et al. (2011), PMID 20819978
Why This Study Mattered
By the time this paper appeared, modern clinical psychedelic research was only beginning to re-emerge after decades of inactivity. That context matters because the bar for the study was not only "does it help?" but also "can this even be done safely and responsibly in a medically fragile population?"
The abstract frames the project exactly that way. It re-opened a long-dormant research question in patients with advanced-stage cancer and reactive anxiety, using a controlled clinical unit rather than a loose or informal setting.
That makes this paper important even before you get to the outcome scales. It helped re-establish that carefully supervised psilocybin research in oncology-adjacent mental health was possible.
What Researchers Actually Tested
The abstract describes a double-blind, placebo-controlled study using a moderate psilocybin dose of 0.2 mg/kg. Twelve adults with advanced-stage cancer and anxiety participated.
The outcomes were not limited to what happened during the dosing day. Follow-up data included measures such as the Beck Depression Inventory, the Profile of Mood States, and the State-Trait Anxiety Inventory, with follow-up extending to 6 months after treatment.
That gives the paper two layers of value:
- safety and tolerability during the treatment sessions
- early signal detection on mood and anxiety after treatment
What The Abstract Shows
The abstract reports that physiological and psychological responses during treatment were safe and that no clinically significant adverse events occurred.
On efficacy-related measures, the strongest stated signal was on the trait anxiety subscale of the State-Trait Anxiety Inventory, which showed significant reduction at 1 and 3 months. Mood also improved, with the Beck Depression Inventory reaching significance at 6 months. Another mood measure moved in the same direction but did not cross the significance line.
That pattern is exactly why the paper is interesting. The signal is not flat or null. But it is also not clean enough to behave like a mature late-stage trial result.
- Mechanistic workmissing
Not part of this study packet.
- Animal workmissing
Not part of this study packet.
- Small human pilotcurrent
12 adults with advanced-stage cancer and anxiety, placebo-controlled, 6-month follow-up.
- Large confirmatory trialsmissing
This study did not provide them.
- Systematic review consensusmissing
This study sat much earlier in the evidence cycle.
This was a serious clinical pilot that helped reopen the field. It was not, by itself, enough to settle the therapeutic case.
RTHM-00397 source packet
What This Study Cannot Tell Us
Several boundaries matter if you want a scientifically serious reading.
- The sample was tiny.
- The abstract says follow-up data were collected unblinded, which weakens the confidence you can place in long-term outcome changes.
- We do not yet have the full text in the packet, so session procedures, participant flow, and exact control details are not fully captured here.
- A vulnerable oncology population makes safety and ethics especially important, but it also means findings should not be generalized casually to every anxiety context.
In other words, this is a foundational paper, not a final paper.
Why It Still Earns Attention
Even with those limits, the study remains important for three reasons.
First, it documents that carefully monitored psilocybin administration in this population was feasible. Second, it reports no clinically significant adverse events in the treatment setting described by the abstract. Third, it found a directionally promising anxiety signal that justified more rigorous follow-up work.
That is a meaningful contribution. It is just a different kind of contribution than "the treatment is now proven."
Rethink Takeaway
If you want the strongest defensible summary, it is this: this study helped show that psilocybin-assisted research in advanced-stage cancer patients with anxiety could be conducted safely in a controlled setting and might produce clinically relevant benefits worth testing further.
That is a major milestone. It is not the same thing as definitive efficacy.
Read the original research
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Archives of general psychiatry, 68(1), 71-8
Citation
Grob, Charles S; Danforth, Alicia L; Chopra, Gurpreet S; Hagerty, Marycie; McKay, Charles R; Halberstadt, Adam L; Greer, George R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.. Archives of general psychiatry, 68(1), 71-8. https://doi.org/10.1001/archgenpsychiatry.2010.116